PATENT CLAIM ANALYSIS

Application Number: 15764687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "480000"]

Abstract:
Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, and allergic, autoimmune, and inflammatory disorders including hematological malignancies. In particular, the methods include administration of a BTK inhibitor and with one or more inhibitor. For example, the one or more inhibitor may be a JAK inhibitor, a ASK1 inhibitor, a BRD4 inhibitor or an MMP9 inhibitor.

Claim (Index 10):
The method of  claims 1  or  6  wherein the MMP9 inhibitor comprises a MMP9 binding protein comprising:\n an immunoglobulin heavy chain polypeptide, or a functional fragment thereof; and \n an immunoglobulin light chain polypeptide, or a functional fragment thereof; wherein the MMP9 binding protein specifically binds to human MMP9, and \n wherein the MMP9 binding protein competes for binding to human MMP9 with an antibody comprising heavy chain CDRs of SEQ ID NOs: 13-15 or light chain CDRs of SEQ ID Nos. 16-18.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.61364
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15319740', '14135812', '15105372', '14254010', '14570655']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7553507259980483
- 35 USC 102 Novelty (BERT): 0.5111900236315747
- Combined Prediction Score: 0.7309346557614009
- Mean Citation Score: 247.382998
- Max Citation Score: 260.51425
- Similarity Product: 162.60339510500432

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test